Zhitong Finance App News, Tasly (600535.SH) issued an announcement. Recently, the company received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue a “Pharmaceutical Clinical Trial Approval Notice” for TDX105 granules.

TDX105 granules are a new traditional Chinese medicine class 1.1 drug developed based on clinical experience at the Cancer Hospital of the Chinese Academy of Medical Sciences (National Cancer Center). The prescription composition and dosage of this product are consistent with clinical application. This clinical experience has been used clinically for many years. Clinical observations show that it has obvious relief effects on skin damage such as itching and pain caused by adverse skin reactions related to cancer treatment drugs, and has good curative efficacy and safety.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.